Please assess the completion status of the following clinical trial:

Trial Title: Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Presence of a renal mass.~2. Scheduled for surgical resection of renal mass.~3. Expected survival of at least 3 months.~4. Karnofsky performance scale ≥70.~5. The following laboratory results should be within the following limits within the last 4 weeks prior to study day 1:~   * Absolute neutrophil count (ANC) ≥ 1.5 x 10E9/L~  * Platelet count ≥ 100 x 10E9/L~  * Serum bilirubin ≤ 2.0 mg/dL~  * Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN)~  * Alanine aminotransferase (ALT) ≤ 2.5 x ULN~  * Serum creatinine ≤ 2.0 mg/dL~6. Pregnancy Test to be performed on female patients of childbearing potential within 24-48 hours before administration of radioactive material.~7. Recovered from toxicity of any prior therapy.~8. Able and willing to give valid written informed consent.~Exclusion Criteria:~1. Intercurrent medical condition that may limit the amount of antibody to be administered.~2. Intercurrent medical condition that renders the patient ineligible for surgery.~3. New York Heart Association Class III/IV cardiac disease.~4. History of autoimmune hepatitis.~5. Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the first cG250 dose.~6. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.~7. Lack of availability for immunological and clinical follow-up assessments.~8. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.~9. Women who are pregnant or breastfeeding.~10. Allergy to iodine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 124I-cG250 (Type: EXPERIMENTAL): Patients who were scheduled for surgical resection of renal masses received a single intravenous (IV) dose of 10 mg of 5 milliCurie (mCi) /10 mg 124I-cG250. Patients underwent Positron-Emission Tomography/Computed Tomography (PET/CT) imaging of the whole body on at least 2 occasions: once following injection and once immediately prior to surgical resection. Patients were scheduled for surgical resection of their renal masses on day 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).